A new arXiv paper argues that drug-target binding affinity prediction improves when models preserve both chemical and geometric details of the interacting molecules. The authors focus on representation fidelity as a way to capture the subtle structural features that determine molecular recognition. The work falls under machine learning research rather than a released product or model.
A new arXiv paper addresses the difficulty of scoring open-ended, tool-using LLM agents in chemistry and drug discovery, where conventional benchmarks fall short. The authors propose an evaluation system built on the LLM-as-a-Judge approach and tune it against human expert judgments to improve reliability. The work aims to make automated assessment of agentic scientific workflows more trustworthy.
A new arXiv paper presents an explainable machine learning framework that predicts blood-brain barrier permeability using molecular descriptors. Since this barrier determines whether central nervous system drug candidates can reach targets in the brain, the approach could support earlier screening in drug development. Its explainable design is intended to reveal which molecular features drive the model's predictions.
A research paper on arXiv examines how large language models can be applied to molecular optimization, the task of designing small molecules with targeted properties. The work positions LLM-based approaches as a promising tool for drug discovery pipelines, where candidate compounds must be iteratively refined to meet specific criteria.
A new arXiv study presents a systematic evaluation of molecule generation models, which are computational tools for exploring chemical space in de novo drug design beyond what traditional virtual screening allows. The authors compare leading approaches across benchmarks and distill practical insights to guide real-world use in drug discovery.
Researchers introduce ProMeta, a few-shot machine learning framework that forecasts how effectively PROTAC molecules degrade target proteins across different E3 ligases. PROTACs are bifunctional compounds that hijack the ubiquitin-proteasome system to eliminate disease-linked proteins long considered out of reach for conventional drugs. The method targets the scarcity of labeled data that has limited prior computational predictors for targeted degradation.
A drug candidate for lung fibrosis that was developed with the help of artificial intelligence produced effects in a study that point to a reduced pace of biological aging. The reported findings come from a single trial and indicate additional effects beyond the compound's intended antifibrotic action. Researchers have not yet established whether these observations translate into clinical benefits for patients.
César de la Fuente's laboratory is applying OpenAI's Codex and ChatGPT to screen genetic data from both living and extinct organisms for potential antimicrobial compounds. The goal is to surface new drug candidates that could help address infections resistant to current antibiotics. The work illustrates how AI coding and language tools are being folded into early-stage biomedical discovery.
WHY IT MATTERS ↘It shows that general-purpose coding and language models can be repurposed as cheap screening instruments in domains like drug discovery, shifting advantage to labs that can wrap them in domain-specific pipelines rather than to whoever trains the frontier model. It also widens the surface for dual-use and biosecurity scrutiny, since the same tooling that surfaces antimicrobial candidates could be pointed at other genomic targets.